CYP19A1 and neoplasm: To investigate features for the evaluation of tumor response related to treatment outcome, we explored the MRI morphological response patterns, prior and subsequent to combined NET with third-generation aromatase inhibitors, with histopathological tumor regression grading system based on tumor cellularity in patients diagnosed with ER-positive /HER-2-negative LABC.